Sonova FY 2025-26 profit beats estimates despite China headwinds By Investing.com

Sonova beat 2025-26 normalized EBITA estimates by 3.9% at CHF 811.2 million versus CHF 780.8 million consensus, while sales were in line at CHF 3.61 billion and the dividend was raised 7% to CHF 4.70 per share. However, reported EBITA fell 5.8% on FX headwinds, cochlear implant sales declined 11.1% in local currency, and the company flagged a 1-2 percentage point drag to Swiss franc sales growth and a 3-4 point drag to core EBIT growth in 2026-27. Guidance for next year calls for 5-8% sales growth and 7-10% core EBIT growth at constant currencies.

Analysis

The clean read-through is that the core franchise is still compounding, but the market is likely to underprice how much of the headline result is being masked by FX and the discontinued consumer drag. That matters because the operating engine is now more exposed to constant-currency growth quality than reported EPS optics; if CHF weakens further, investors may keep discounting otherwise resilient execution even as underlying margins stay above plan. The real positive is that hearing instruments are still carrying the mix, which suggests pricing power and channel discipline remain intact despite a softer macro backdrop.

The negative surprise is less the implants miss than the China-specific volume-procurement issue, which creates a second-order risk: once procurement frameworks compress ASPs, competitors can rationally chase share by offering lower price points, potentially forcing a category-wide reset rather than a single-company issue. That could keep the implant business structurally de-rated for several quarters, and it also raises the risk that management’s consolidated growth guide is more dependent on hearing instruments than investors want to admit. In other words, the multiple should bifurcate between the stable, cash-generative hearing segment and the policy-sensitive implant exposure.

Dividend growth plus lower net debt should support the stock on the downside, but the short-term catalyst path is clear: FX moves and any signal on the consumer divestiture close will matter more than the annual guide itself over the next 1-3 months. The contrarian setup is that consensus may be too focused on the miss in China and not enough on the quality of gross margin and cash generation; if the divestiture is executed cleanly, reported earnings power can rerate quickly as the market stops capitalizing a dying asset. Conversely, if CHF strength persists, reported growth could look sluggish for another two quarters even with solid underlying demand, creating a better entry point on dips than chasing after the print.

Key Decisions for Investors

• Long SONVY on weakness over the next 2-6 weeks with a 6-9 month horizon: the setup favors a rerate if the consumer divestiture proceeds and constant-currency growth remains in the mid-single digits; target 10-15% upside, stop if China implant weakness broadens beyond one segment.
• Pair trade: long SONVY / short a more FX-sensitive Swiss healthcare name for the next 1-3 months to isolate idiosyncratic operating strength from reported-currency noise; this works best if CHF stays firm and the market punishes the headline EPS translation.
• Buy SONVY dividend-supported downside protection via put spreads into the next 4-8 weeks if the stock rallies on the guide; the objective is to monetize elevated expectations around the divestiture while limiting premium outlay.
• Avoid adding exposure to implant-exposed medtech names with China procurement risk for 1-2 quarters; the policy overhang can compress margins faster than consensus models allow, and Sonova's miss is a warning signal for the subsector.
• If SONVY gaps down >5% on the print, accumulate in tranches rather than all at once: the operating quality plus capital return profile makes forced seller-driven dislocations attractive, but the China narrative could linger and keep the stock range-bound for 1-2 earnings cycles.